The 2011 EBCTCG polychemotherapy overview

The Lancet

Volumn 379, Issue 9814, 2012, Pages 390-392

  Palmieri, Carlo ^a   Jones, Alison ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TAXANE DERIVATIVE; TRASTUZUMAB;

ACUTE GRANULOCYTIC LEUKEMIA; BLOOD TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURVIVAL; CARDIOTOXICITY; COMPARATIVE STUDY; DRUG EFFICACY; FOLLOW UP; HUMAN; META ANALYSIS (TOPIC); NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION;

EID: 84856681188     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)61823-0     Document Type: Note

References (12)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials Lancet 2011 10.1016/S0140-6736(11)61625-5 published online Dec 6.
2. G Bonadonna, E Brusamolino, P Valagussa et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer N Engl J Med 294 1976 405 410
3. S Darby, C Davies, P Gale The Early Breast Cancer Trialists' Collaborative Group: a brief history of results to date AC Davison Y Dodge N Wermuth Celebrating statistics 2005 Oxford University Press Oxford
4. DD Von Hoff, M Rozencweig, M Layard, M Slavik, FM Muggia Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases Am J Med 62 1977 200 208 (Pubitemid 8042834)
5. MJ Piccart-Gebhart, M Procter, B Leyland-Jones et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
6. J Baselga, L Norton, J Albanell et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts Cancer Res 58 1998 2825 2831 (Pubitemid 28311914)
7. EA Perez, VJ Suman, N Davidson et al. NCCTG N9831. May 2005 update. Slide presentation at the 41st American Society of Clinical Oncology Annual Meeting; Orlando, FL, USA; May 13-17, 2005 http://media.asco.org/player/default.aspx? LectureID=5815&conferenceFolder=VM2005&SessionFolder=SS11&slideonly= yes&TrackID=N92null&LectureTitle= Presenter3a20Further20Analysis20of20NCCTG-N9831&Key=vm-34-2-1708- 19091&SpeakerName=Edith20A.20Perez2c20MD&mediaURL=2fmedia& ServerName=media.asco.org&max=24&ext=jpg&useASX=false&playtype= &playtype=&playtype= (accessed Nov 28, 2011).
8. DA Berry, C Cirrincione, IC Henderson et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 2006 1658 1667
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 2005 1687 1717
10. T Sørlie, CM Perou, R Tibshirani et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci USA 98 2001 10869 10874 (Pubitemid 32878711)
11. H Kennecke, R Yerushalmi, R Woods et al. Metastatic behavior of breast cancer subtypes J Clin Oncol 28 2010 3271 3277
12. KS Albain, WE Barlow, S Shak for The Breast Cancer Intergroup of North America Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial Lancet Oncol 11 2010 55 65